Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction?

  title={Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction?},
  author={Eva M Lonn},
  journal={Current Opinion in Hematology},
  • E. Lonn
  • Published 1 September 2007
  • Medicine, Biology
  • Current Opinion in Hematology
Purpose of reviewHomocysteine has been proposed as a potentially modifiable risk factor for arterial and venous vascular disease. This notion is supported by a large body of literature derived from observations in patients with rare inborn errors of metabolism associated with homocystinuria, experimental studies, which show that homocysteine promotes atherogenesis and thrombosis and epidemiological studies, which in general suggest a graded and independent relationship between homocysteine and… 

Homocysteine-lowering interventions for preventing cardiovascular events.

Whether homocysteine-lowering interventions, provided to patients with and without pre-existing cardiovascular disease are effective in preventing cardiovascular events, as well as reducing all-cause mortality, and to evaluate their safety is evaluated.

Homocysteine: An Emerging Cardiovascular Risk Factor that Never Really Made it~!2009-10-29~!2009-12-27~!2010-04-08~!

Recent meta- analyses of prospective observational studies and randomized controlled trials failed to show a role of tHcy in the patho- genesis of vascular disease or a benefit of B vitamins in CVD events.

Homocysteine – from disease biomarker to disease prevention

It is concluded that total homocysteine values in adults of 10 μmol/L or below are probably safe, but that values of 11 μmol /L or above may justify intervention.

A Review of Hereditary and Acquired Coagulation Disorders in the Aetiology of Ischaemic Stroke

Large prospective population-based studies allowing the evaluation of interactive and subgroup effects are required to appreciate the role of coagulation disorders in the pathophysiology of arterial ischaemic stroke and to guide the management of individual patients.

Homocysteine, the Cholesterol of the 21st Century. Impact of Hyperhomocysteinemia on Patency and Amputation-Free Survival after Intervention for Critical Limb Ischemia

  • H. HeneghanS. Sultan
  • Medicine
    Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists
  • 2008
Hyperhomocysteinemia appears to be an independent risk factor for the progression of vascular disease and is an adverse prognostic factor for CLI patients undergoing peripheral arterial revascularization.

Risk factors for ischemic stroke and transient ischemic attack in patients under age 50

Thrombophilia investigation and/or autoimmune serology should be restricted to patients without conventional cardiovascular risk factors and a history or other clinical symptoms associated with hypercoagulability and/ or autoimmune diseases, according to this younger population under the age of 50.

Tratamento dietético da hiper-homocisteinemia na doença arterial periférica

Although the use of folate is a cost-effective therapy for the control of hyperhomocysteinemia, its impact on the evolution of vascular diseases remains inconclusive.

Serum homocysteine in deep venous thrombosis, peripheral atherosclerosis and healthy Iranians: a case-control study.

The association between homocysteine and atherosclerosis and deep vein thrombosis was not confirmed in this study and it is possible that this association fades away in populations with high prevalence of hyperhomocysteinema.

Screening for coagulation disorders in patients with ischemic stroke

The usefulness of screening stroke patients for prothrombotic conditions and current recommendations regarding the optimal management of ischemic stroke patients in whom a coagulation disorder is found are discussed.



Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated.

Homocysteine-Lowering Therapy and Risk for Venous Thromboembolism

Investigation of a large randomized, placebo-controlled trial of folic acid and B vitamins to reduce cardiovascular events investigated the effect of homocysteine lowering on venous thromboembolism, and found it did not reduce the incidence of venousThrombosis.

Homocysteine and atherothrombosis

There is in fact no clear evidence for a causal role of homocysteine in the pathogenesis of atherothrombotic disease, and the positive association between plasma homocystinuric pateints and II ID observed in many, but not all epidemiologic studies does not prove causality.

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

Whether the association of serum homocysteine concentration with ischaemic heart disease, deep vein thrombosis and pulmonary embolism, and stroke is causal and, if so, to quantify the effect of homocy Steine reduction in preventing them, there is strong evidence that the association between homocy steine and cardiovascular disease is causal.

Homocysteine and Cardiovascular Disease

After a thorough review of the available literature, it appears that hyperhomocysteinemia is an independent risk factor for CHD. Furthermore, folic acid has been shown to reduce homocysteine

Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

In this trial, moderate reduction of total homocysteine after nondisabling cerebral infarction had no effect on vascular outcomes during the 2 years of follow-up, and the consistent findings of an association of totalhomocysteines with vascular risk suggests that further exploration of the hypothesis is warranted and longer trials in different populations with elevated total homocrysteine may be necessary.

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.

This meta-analysis of observational studies suggests that elevated homocysteine is at most a modest independent predictor of IHD and stroke risk in healthy populations.

Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence

Although simple, inexpensive, nontoxic therapy with folate and vitamins B6 and B12 is highly effective at reducing plasma homocysteine levels, it remains to be demonstrated that decreasing homocyst(e)ine levels reduces cardiovascular morbidity and mortality.

A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

Higher folic acid intake by reducing tHcy levels promises to prevent arteriosclerotic vascular disease and under different assumptions, 13,500 to 50,000 CAD deaths annually could be avoided.